Posted by Michael Wonder on 09 May 2022
Product information update for COVID-19 treatment Xevudy (sotrovimab)
6 May 2022 - On 7 April 2022, the TGA announced receipt of an application from GSK for a higher (1000 mg) dose of its COVID-19 treatment Xevudy (sotrovimab).
This application is being considered for the treatment of patients suspected to have infection caused by the Omicron BA.2 sublineage, which has become the dominant strain of COVID-19.
